---
title: "BIOTEST BIOTECH released its semi-annual performance, with a net profit attributable to the parent company of 12.4 million yuan, a year-on-year decrease of 82.82%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254954370.md"
description: "According to the Zhitong Finance APP, BIOTEST BIOTECH disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 203 million yuan, a year-on-year decrease of 23.91%; net profit attributable to the parent company was 12.4 million yuan, a year-on-year decrease of 82.82%; net profit excluding non-recurring items was 6.83 million yuan, a year-on-year decrease of 90.25%; basic earnings per share were 0.07 yuan"
datetime: "2025-08-28T08:40:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254954370.md)
  - [en](https://longbridge.com/en/news/254954370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254954370.md)
---

# BIOTEST BIOTECH released its semi-annual performance, with a net profit attributable to the parent company of 12.4 million yuan, a year-on-year decrease of 82.82%

According to the Zhitong Finance APP, BIOTEST BIOTECH (688767.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 203 million yuan, a year-on-year decrease of 23.91%; net profit attributable to the parent company was 12.4 million yuan, a year-on-year decrease of 82.82%; net profit excluding non-recurring gains and losses was 6.83 million yuan, a year-on-year decrease of 90.25%; basic earnings per share were 0.07 yuan

### Related Stocks

- [688767.CN](https://longbridge.com/en/quote/688767.CN.md)

## Related News & Research

- [Is RFK's 'carnivore diet' healthy? Here's what you need to know.](https://longbridge.com/en/news/286951172.md)
- [Why Indian PE funds are betting big on consumer brands and manufacturing](https://longbridge.com/en/news/286875914.md)
- [Việt Nam eyes balanced, sustainable trade ties with US](https://longbridge.com/en/news/286951723.md)
- [REA says Indonesian CPO export board plan has limited direct impact, flags price risk](https://longbridge.com/en/news/287031625.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)